Woodline Partners’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-127,371
| Closed | -$4.3M | – | 605 |
|
|
2023
Q4 | $4.3M | Buy |
127,371
+18,964
| +17% | +$640K | 0.05% | 329 |
|
|
2023
Q3 | $3.33M | Buy |
108,407
+31
| +0% | +$951 | 0.04% | 353 |
|
|
2023
Q2 | $4.34M | Buy |
108,376
+5
| +0% | +$200 | 0.05% | 309 |
|
|
2023
Q1 | $4.42M | Buy |
108,371
+17,724
| +20% | +$723K | 0.06% | 311 |
|
|
2022
Q4 | $3.5M | Sell |
90,647
-464
| -0.5% | -$17.9K | 0.05% | 378 |
|
|
2022
Q3 | $4.85M | Buy |
91,111
+3,279
| +4% | +$174K | 0.07% | 298 |
|
|
2022
Q2 | $5.12M | Buy |
87,832
+32
| +0% | +$1.87K | 0.08% | 257 |
|
|
2022
Q1 | $6.7M | Hold |
87,800
| – | – | 0.11% | 216 |
|
|
2021
Q4 | $5.28M | Buy |
+87,800
| New | +$5.28M | 0.08% | 275 |
|
|
2020
Q3 | – | Sell |
-200,720
| Closed | -$10.5M | – | 209 |
|
|
2020
Q2 | $10.5M | Buy |
200,720
+8,488
| +4% | +$445K | 0.42% | 71 |
|
|
2020
Q1 | $6.45M | Sell |
192,232
-199,236
| -51% | -$6.68M | 0.46% | 69 |
|
|
2019
Q4 | $17.7M | Buy |
+391,468
| New | +$17.7M | 0.72% | 49 |
|